Literature DB >> 10605043

The Arthus reaction in rodents: species-specific requirement of complement.

A J Szalai1, S B Digerness, A Agrawal, J F Kearney, R P Bucy, S Niwas, J M Kilpatrick, Y S Babu, J E Volanakis.   

Abstract

We induced reverse passive Arthus (RPA) reactions in the skin of rodents and found that the contribution of complement to immune complex-mediated inflammation is species specific. Complement was found to be necessary in rats and guinea pigs but not in C57BL/6J mice. In rats, within 4 h after initiation of an RPA reaction, serum alternative pathway hemolytic titers decreased significantly below basal levels, whereas classical pathway titers were unchanged. Thus the dermal reaction proceeds coincident with systemic activation of complement. The serine protease inhibitor BCX 1470, which blocks the esterolytic and hemolytic activities of the complement enzymes Cls and factor D in vitro, also blocked development of RPA-induced edema in the rat. These data support the proposal that complement-mediated processes are of major importance in the Arthus reaction in rats and guinea pigs, and suggest that BCX 1470 will be useful as an anti-inflammatory agent in diseases where complement activation is known to be detrimental.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10605043     DOI: 10.4049/jimmunol.164.1.463

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Complement-targeted therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

2.  Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fcgamma receptors.

Authors:  Rangaiah Shashidharamurthy; Randolph A Hennigar; Sebastien Fuchs; Purani Palaniswami; Melanie Sherman; Periasamy Selvaraj
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

3.  Role for complement in the development of seizures following acute viral infection.

Authors:  Jane E Libbey; Nikki J Kirkman; Karen S Wilcox; H Steve White; Robert S Fujinami
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

4.  Discovery and Structural Modification of 1-Phenyl-3-(1-phenylethyl)urea Derivatives as Inhibitors of Complement.

Authors:  Mei Zhang; Xiao-Ying Yang; Wei Tang; Tom W L Groeneveld; Pei-Lan He; Feng-Hua Zhu; Jia Li; Wei Lu; Anna M Blom; Jian-Ping Zuo; Fa-Jun Nan
Journal:  ACS Med Chem Lett       Date:  2012-02-27       Impact factor: 4.345

5.  Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance.

Authors:  Aaron L Nelson; Aoife M Roche; Jane M Gould; Kannie Chim; Adam J Ratner; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

6.  Overlapping roles of endothelial selectins and vascular cell adhesion molecule-1 in immune complex-induced leukocyte recruitment in the cremasteric microvasculature.

Authors:  M Ursula Norman; Nicholas C Van De Velde; Jennifer R Timoshanko; Andrew Issekutz; Michael J Hickey
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

7.  The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model.

Authors:  D Bogaert; C M Thompson; K Trzcinski; R Malley; M Lipsitch
Journal:  Vaccine       Date:  2009-11-03       Impact factor: 3.641

Review 8.  Recent developments in low molecular weight complement inhibitors.

Authors:  Hongchang Qu; Daniel Ricklin; John D Lambris
Journal:  Mol Immunol       Date:  2009-10-02       Impact factor: 4.407

9.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

10.  Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction.

Authors:  Jessica L Teeling; Roxana O Carare; Martin J Glennie; V Hugh Perry
Journal:  Acta Neuropathol       Date:  2012-05-18       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.